Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
US9907849B2 · kind B2 · utility
7Cited by
24References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 17, 2015 |
| Grant date | Mar 6, 2018 |
| Priority date | — |
| Expiry date | Jul 17, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/884
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.